Denmark zoo asks people to donate their small pets as food for captive predators
The Aalborg zoo said it is trying to mimic the natural food chain of the animals housed there 'for the sake of both animal welfare and professional integrity' and offers assurances the pets will be 'gently euthanized' by trained staff.
The zoo in northern Denmark explained in a Facebook post that 'if you have a healthy animal that needs to be given away for various reasons, feel free to donate it to us.'
The zoo points to guinea pigs, rabbits and chickens as possible donations. After being euthanized, the animals will be used as fodder, the zoo said.
'That way, nothing goes to waste — and we ensure natural behavior, nutrition and well-being of our predators,' the zoo said.
The online call for pet donations is accompanied by a picture of a wildcat baring its teeth with its mouth wide open and a link to the zoo's website, noting the facility also is interested in receiving horses.
The zoo, which could not immediately be reached for additional details, does not list other pets or animals as possible donations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Eating fewer ultra-processed foods could boost weight loss, trial suggests
Eating minimally processed foods and avoiding ultra processed foods (UPFs) could help people lose twice as much weight, a new trial has found. Sticking to meals cooked from scratch could also help curb food cravings, researchers suggest. UPFs include the likes of processed meals, ice cream, crisps, some breakfast cereals, biscuits and fizzy drinks. They tend to have high levels of saturated fat, salt and sugar, as well as additives and ingredients that are not used when people cook from scratch, like preservatives, emulsifiers and artificial colours and flavours. The trial, led by experts at University College London (UCL) and University College London Hospitals NHS Foundation Trust (UCLH), involved 55 people split into two groups. Half were given an eight-week diet plan comprising minimally processed foods, such as overnight oats and spaghetti bolognese, while the other half were given foods like breakfast oat bars or lasagne ready meals. After completing one diet, the groups then switched. Researchers matched the two diets nutritionally on levels of fat, saturated fat, protein, carbohydrates, salt and fibre using the Eatwell Guide, which outlines recommendations on how to eat a healthy, balanced diet. Dr Samuel Dicken, of the UCL Centre for Obesity Research and UCL department of behavioural science and health, said: 'Previous research has linked ultra-processed foods with poor health outcomes. 'But not all ultra-processed foods are inherently unhealthy based on their nutritional profile.' He said the main aim of the study was to explore the role of food processing and how it impacts weight, blood pressure, body composition and food cravings. Some 50 people completed the trial, with both groups losing weight. However, those on the minimally processed diet lost more weight (2.06%) compared to the UPF diet (1.05% loss). The UPF diet also did not result in significant fat loss, researchers said. Dr Dicken said: 'Though a 2% reduction may not seem very big, that is only over eight weeks and without people trying to actively reduce their intake. 'If we scaled these results up over the course of a year, we'd expect to see a 13% weight reduction in men and a 9% reduction in women on the minimally processed diet, but only a 4% weight reduction in men and 5% in women after the ultra-processed diet. 'Over time this would start to become a big difference.' Those on the trial were also asked to complete questionnaires on food cravings before and after starting the diets. Those eating minimally processed foods had less cravings and were able to resist them better, the study suggests. However, researchers also measured others markers like blood pressure, heart rate, liver function, glucose levels and cholesterol and found no significant negative impacts of the UPF diet. Professor Chris van Tulleken, of the UCL division of infection and immunity and UCLH, said: 'The global food system at the moment drives diet-related poor health and obesity, particularly because of the wide availability of cheap, unhealthy food. 'This study highlights the importance of ultra-processing in driving health outcomes in addition to the role of nutrients like fat, salt and sugar.' The Eatwell Guide recommends the average woman should consume around 2,000 calories a day, while an average man should consume 2,500. Both diet groups had a calorie deficit, meaning people were eating fewer calories than what they were burning, which helps with weight loss. However, the deficit was higher from minimally processed foods at around 230 calories a day, compared with 120 calories per day from UPFs. Professor Rachel Batterham, senior author of the study from the UCL centre for obesity research, said: 'Despite being widely promoted, less than 1% of the UK population follows all of the recommendations in the Eatwell Guide, and most people stick to fewer than half. 'The normal diets of the trial participants tended to be outside national nutritional guidelines and included an above average proportion of UPF, which may help to explain why switching to a trial diet consisting entirely of UPF, but that was nutritionally balanced, resulted in neutral or slightly favourable changes to some secondary health markers. 'The best advice to people would be to stick as closely to nutritional guidelines as they can by moderating overall energy intake, limiting intake of salt, sugar and saturated fat, and prioritising high-fibre foods such as fruits, vegetables, pulses and nuts. 'Choosing less processed options such as whole foods and cooking from scratch, rather than ultra-processed, packaged foods or ready meals, is likely to offer additional benefits in terms of body weight, body composition and overall health.' Commenting on the study, Tracy Parker, nutrition lead at the British Heart Foundation, said: 'These findings support what we have long suspected – that the way food is made might affect our health, not just the nutrients it contains. 'The way this study was designed means it is more reflective of real-world conditions than previous research on ultra-processed foods. 'Unlike earlier observational studies, this was a randomised controlled trial where participants were provided with all their meals, and the diets were carefully matched to meet the Eatwell Guide – this allowed researchers to isolate the effect of food processing itself, making it more likely that the differences seen after eight weeks were due to how the food in their diets was processed, not just what was in it. 'Completely cutting UPFs out of our diets isn't realistic for most of us, but including more minimally processed foods – like fresh or home cooked meals – alongside a balanced diet could offer added benefits too. 'Mediterranean-style diets, which include plenty of minimally or unprocessed foods such as fruit, vegetables, fish, nuts and seeds, beans, lentils and wholegrains, have consistently been shown to reduce our risk of heart attacks and strokes.'
San Francisco Chronicle
an hour ago
- San Francisco Chronicle
Scientists say they have solved the mystery of what killed more than 5 billion sea stars
WASHINGTON (AP) — Scientists say they have at last solved the mystery of what killed more than 5 billion sea stars off the Pacific coast of North America in a decade-long epidemic. Sea stars – often known as starfish – typically have five arms and some species sport up to 24 arms. They range in color from solid orange to tapestries of orange, purple, brown and green. Starting in 2013, a mysterious sea star wasting disease sparked a mass die-off from Mexico to Alaska. The epidemic has devastated more than 20 species and continues today. Worst hit was a species called the sunflower sea star, which lost around 90% of its population in the outbreak's first five years. 'It's really quite gruesome,' said marine disease ecologist Alyssa Gehman at the Hakai Institute in British Columbia, Canada, who helped pinpoint the cause. Healthy sea stars have 'puffy arms sticking straight out,' she said. But the wasting disease causes them to grow lesions and 'then their arms actually fall off.' The culprit? Bacteria that has also infected shellfish, according to a study published Monday in the journal Nature Ecology and Evolution. The findings 'solve a long-standing question about a very serious disease in the ocean," said Rebecca Vega Thurber, a marine microbiologist at University of California, Santa Barbara, who was not involved in the study. It took more than a decade for researchers to identify the cause of the disease, with many false leads and twists and turns along the way. Early research hinted the cause might be a virus, but it turned out the densovirus that scientists initially focused on was actually a normal resident inside healthy sea stars and not associated with disease, said Melanie Prentice of the Hakai Institute, co-author of the new study. Other efforts missed the real killer because researchers studied tissue samples of dead sea stars that no longer contained the bodily fluid that surrounds the organs. But the latest study includes detailed analysis of this fluid, called coelomic fluid, where the bacteria Vibrio pectenicida were found. 'It's incredibly difficult to trace the source of so many environmental diseases, especially underwater,' said microbiologist Blake Ushijima of the University of North Carolina, Wilmington, who was not involved in the research. He said the detective work by this team was 'really smart and significant.' Now that scientists know the cause, they have a better shot at intervening to help sea stars. Prentice said that scientists could potentially now test which of the remaining sea stars are still healthy — and consider whether to relocate them, or breed them in captivity to later transplant them to areas that have lost almost all their sunflower sea stars. Scientists may also test if some populations have natural immunity, and if treatments like probiotics may help boost immunity to the disease. Such recovery work is not only important for sea stars, but for entire Pacific ecosystems because healthy starfish gobble up excess sea urchins, researchers say. Sunflower sea stars 'look sort of innocent when you see them, but they eat almost everything that lives on the bottom of the ocean,' said Gehman. 'They're voracious eaters.' With many fewer sea stars, the sea urchins that they usually munch on exploded in population – and in turn gobbled up around 95% of the kelp forest s in Northern California within a decade. These kelp forests provide food and habitat for a wide variety of animals including fish, sea otters and seals. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
2 hours ago
- Yahoo
Freya Pharma Solutions Announces Launch of Phase II Clinical Dose-Response Study testing its LybridoTM Concept Targeting Female Sexual Dysfunction
evaluates Lybrido™'s Dual-Action therapy for Female Sexual Dysfunction Innovative clitoral blood flow measurement technique aims to objectively quantify treatment efficacy of two dose-combinations ALETTA Pivotal Study prepared for Late 2025 launch in Europe amid significant unmet medical need Amsterdam, the Netherlands, 4 August 2025 - Freya Pharma Solutions, a pharmaceutical company specializing in innovative therapies for women diagnosed with Female Sexual Disorders (FSD), today announced the initation of a Phase II clinical study evaluating its LybridoTM concept. The study will investigate two dose-combinations of testosterone and sildenafil, assessing their effects on female sexual response through physiological measurements of genital blood flow parameters. This investigator-initiated clinical study, designed and led by Princial Investigator Prof. Cobi Reisman, (urologist, sexologist), and Co-Investigator Dr. Anna Padoa (gynecologist), will be conducted at the Chaim Sheba Medical Center. The study aims to assess objective physiological measurements of arousal response in premenopausal women diagnosed with acquired generalized Female Sexual Interest/Arousal Disorder (FSIAD) following treatment with combined sublingual testosterone and oral sildenafil therapy. Clitoral blood flow parameters – a key biomarker of genital arousal - will be quantified using standardized Clitoral Doppler Duplex Ultrasound imaging. Prof. Cobi Reisman, MD, PhD, FCESM,ECPS said: 'Combination therapy of sublingual testosterone and oral sildenafil is reported as a potentially effective and safe treatment option for premenopausal women with FSIAD. We are very interested in this promising treatment modality, and aim to better understand the mechanisms behind the clinical observations reported sofar. Sexual function is frequently measured with validated and standardized questionnaires to determine the subjective sexual response, whereas objective measures warrant physical measurement. In this regard, clitoral vascularization is reported as a relevant physiological indicator of the female genital arousal response. In our study we will use Clitoral Doppler Duplex Ultrasound which is a promising technique to assess clitoral blood flow in women.' Dr. Jan van der Mooren, Chief Medical Officer at Freya Pharma Solutions commented:"The combination of sublingual testosterone and oral sildenafil being studied by Prof. Reisman and Dr. Padoa closely mirrors the mechanism of action of LybridoTM, our investigational product for women diagnosed with FSIAD. This research aligns with Freya Pharma's commitment to advancing science in this field, and we're proud to support a study that could deepen our understanding of LybridoTM's therapeutic potential. Concurrently, Freya Pharma Solutions is finalizing preparations for the ALETTA clinical study - a pivotal clinical study as part of Lybrido™'s European clinical development program. Enrollment is slated to begin in late 2025 across 20 European research sites in five countries.' About Female Sexual Disorders Among female sexual disorders (FSD), representing a significant health concern, low sexual desire consistently is reported as the most common issue affecting women. This widespread challenge often leads to clinically significant distress, dissatisfaction in intimate relationships, profoundly impacting emotional well-being and social connections. In the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), Female Sexual Interest/Arousal Disorder (FSIAD) combines persistent reductions in both sexual interest and/or arousal, requiring symptoms to persist for six months, while causing clinically significant distress. Clinicians diagnose FSIAD through specific symptom thresholds and further categorize it by severity (mild, moderate, or severe) and subtype: lifelong versus acquired, and generalized versus situational presentations. FSIAD is the clustering of Hypoactive Sexual Desire Disorder and Female Sexual Arousal Disorder; listed in the World Health Organization's International Classification of Diseases, 11th Revision (ICD-11) under Code 17 HA00/HA01.0 Hypoactive Sexual Desire Dysfunction and Female Sexual Arousal Dysfunction ( About LybridoTM A total of 20 phase I and phase IIa trials, and large-scale phase IIb trials in 17 research sites in the US have been conducted to date. These trials have investigated the efficacy and safety of two novel on-demand pharmacological treatments that have been designed to treat FSIAD, LybridoTM and LybridosTM. LybridoTM increases central sexual motivation and physiological sexual responses, such as swelling of genitals and lubrication. The therapy can be taken 'on-demand' and helps to increase central sexual motivation from 3 to 6 hours after intake. This treatment consists of a novel (dual-route, dual-release, fixed-dose) combination tablet, consisting of a testosterone coating for sublingual administration and an inner-core component containing the phosphodiesterase type 5 (PDE 5) inhibitor, sildenafil. The inner-core component is coated with a delayed-immediate-release matrix to ensure that the peak plasma concentration of the PDE 5 inhibitor coincides with the window of increased sexual motivation induced by the sublingually administered testosterone. Thus, this combination enables an increase in genital arousal through an increase in responsivity to sexual stimuli. About Freya Pharma Solutions Freya Pharma Solutions is a pharmaceutical company, focused on developing effective pharmaceutical therapies for FSIAD/HSDD, building upon fifteen years of solid research. The company's core asset under development is LybridoTM, designed to address FSIAD/HSDD. Based in Amsterdam, The Netherlands, Freya Pharma Solutions aims to offer patients a convenient, personalized 'on-demand' solution for this recognized unmet medical need. For further information please contact: Freya Pharma Solutions, Amsterdam Marcel Wijma, Chief Business Officermarcel@ For media LifeSpring Life Sciences Communication, Amsterdam, the NetherlandsLeon Melens T: +31 6 538 16 427 E: lmelens@ Attachment Freya Pharma Press Release CDU Trial finalSign in to access your portfolio
